Fully integrated, pioneering and always ambitious. Here at Lonza, we are helping to drive innovation and change in the Biologics industry.
We partner with companies to develop innovative therapies and vaccines, from the smallest start-ups to global pharmaceutical companies. From synthetic biology to state-of-the-art manufacturing, we support our customers on a diverse range of projects.
Search open roles and start your journey today
Who are we?
We are around 7,500 talented colleagues working across a wide range of technologies.
In Biologics, you have the opportunity to gain a unique view across hundreds of innovative molecules spanning antibodies, recombinant proteins, bioconjugates, mRNA and other emerging modalities.
Our 11 sites across the globe offer opportunities for discovering new cultures as well as technology. Our services overlap and integrate, providing you with access and insight into all aspects of our business.
The work is complex, so you will have opportunities to learn and develop from the start. It means a career of real value and a future filled with possibilities.
Biologics Manufacturing Footprint
Hear from our people
Lonza has a reputation for manufacturing high quality products that live up to the ‘Swiss made’ label, and I was curious to know the recipe behind this success and keen to be part of it. A huge part of the success is because of the people. The commitment to colleagues at all levels and everyone’s dedication to the organization’s purpose make all the difference.
Echrak Scientist Team lead in Data Science and Digital innovation, Ibex™ SolutionsVisp, Switzerland
I provide critical technical support and troubleshoot process-related issues during the production of a range of life saving medicines. Being part of one of the world’s top biologics manufacturing organizations is incredible.
Madhu Senior Process Engineer, Mammalian ManufacturingSingapore
There were two reasons that I decided to join Lonza. Firstly, there were many opportunities for career growth. Secondly, there was the chance to contribute towards treatments and therapies for the future. It was the right decision on both counts.
Stella Section Manager, Development ServicesSingapore